EPAS1 and telomere syndrome: Of note, treatment with the chromatin modifying agent suberanilohydroxamic acid (SAHA, Sigma-Aldrich, St Louis, MO, USA; Vorinostat), a clinically approved histone deacetylase inhibitor (HDACi)32, significantly increased HIF-2α expression in several STS, and inhibited growth in a HIF-2α dependent manner.